Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech | oneFAPvoice

welcome to oneFAPvoice

- a positively charged Familial Adenomatous Polyposis community.
  • join today!

Microlin Bio to Acquire Nucleic Acid Therapeutic Assets of Marina Biotech


Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, and Marina Biotech, Inc., a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced that the companies have executed a term sheet under which Microlin intends to acquire Marina’s nucleic acid therapeutics assets.

https://www.fapvoice.com/wp-content/uploads/2016/08/20.jpg

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close